| Literature DB >> 30206078 |
Léa Maitre1,2,3, Jeroen de Bont1,2,3, Maribel Casas1,2,3, Oliver Robinson1,2,3,4, Gunn Marit Aasvang5, Lydiane Agier6, Sandra Andrušaitytė7, Ferran Ballester3,8,9, Xavier Basagaña1,2,3, Eva Borràs2,10, Céline Brochot11, Mariona Bustamante1,2,3,10, Angel Carracedo12,13, Montserrat de Castro1,2,3, Audrius Dedele7, David Donaire-Gonzalez1,2,3, Xavier Estivill14,15, Jorunn Evandt5, Serena Fossati1,2,3, Lise Giorgis-Allemand6, Juan R Gonzalez1,2,3, Berit Granum5, Regina Grazuleviciene7, Kristine Bjerve Gützkow5, Line Småstuen Haug5, Carles Hernandez-Ferrer1,2,3, Barbara Heude16, Jesus Ibarluzea3,17,18,19, Jordi Julvez1,2,3,4, Marianna Karachaliou20, Hector C Keun21, Norun Hjertager Krog5, Chung-Ho E Lau21,22, Vasiliki Leventakou20, Sarah Lyon-Caen6, Cyntia Manzano1,2,3, Dan Mason23, Rosemary McEachan23, Helle Margrete Meltzer5, Inga Petraviciene7, Joane Quentin6, Theano Roumeliotaki20, Eduard Sabido2, Pierre-Jean Saulnier24, Alexandros P Siskos21, Valérie Siroux6, Jordi Sunyer1,2,3,4, Ibon Tamayo1,3,25, Jose Urquiza1,2,3, Marina Vafeiadi20, Diana van Gent1,2,3, Marta Vives-Usano1,2,3,10, Dagmar Waiblinger23, Charline Warembourg1,2,3, Leda Chatzi26,27, Muireann Coen22, Peter van den Hazel28, Mark J Nieuwenhuijsen1,2,3, Rémy Slama6, Cathrine Thomsen5, John Wright23, Martine Vrijheid1,2,3.
Abstract
PURPOSE: Essential to exposome research is the collection of data on many environmental exposures from different domains in the same subjects. The aim of the Human Early Life Exposome (HELIX) study was to measure and describe multiple environmental exposures during early life (pregnancy and childhood) in a prospective cohort and associate these exposures with molecular omics signatures and child health outcomes. Here, we describe recruitment, measurements available and baseline data of the HELIX study populations. PARTICIPANTS: The HELIX study represents a collaborative project across six established and ongoing longitudinal population-based birth cohort studies in six European countries (France, Greece, Lithuania, Norway, Spain and the UK). HELIX used a multilevel study design with the entire study population totalling 31 472 mother-child pairs, recruited during pregnancy, in the six existing cohorts (first level); a subcohort of 1301 mother-child pairs where biomarkers, omics signatures and child health outcomes were measured at age 6-11 years (second level) and repeat-sampling panel studies with around 150 children and 150 pregnant women aimed at collecting personal exposure data (third level). FINDINGS TO DATE: Cohort data include urban environment, hazardous substances and lifestyle-related exposures for women during pregnancy and their offspring from birth until 6-11 years. Common, standardised protocols were used to collect biological samples, measure exposure biomarkers and omics signatures and assess child health across the six cohorts. Baseline data of the cohort show substantial variation in health outcomes and determinants between the six countries, for example, in family affluence levels, tobacco smoking, physical activity, dietary habits and prevalence of childhood obesity, asthma, allergies and attention deficit hyperactivity disorder. FUTURE PLANS: HELIX study results will inform on the early life exposome and its association with molecular omics signatures and child health outcomes. Cohort data are accessible for future research involving researchers external to the project. © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: birth cohort; community child health; epidemiology; exposome; omics; public health
Mesh:
Substances:
Year: 2018 PMID: 30206078 PMCID: PMC6144482 DOI: 10.1136/bmjopen-2017-021311
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of the cohorts contributing to the HELIX cohort
| Cohort | Recruitment in original cohort | Exclusions made during recruitment | Years of birth | Region covered by HELIX | No. of births in HELIX entire cohort |
| BiB, UK | All pregnant women who attended the oral glucose tolerance test clinic at Bradford Royal Infirmary in weeks 26–28 of pregnancy. | Women who planned to move away from Bradford before birth were excluded. | 2007–2010 | Bradford | 10 849 |
| EDEN, France | Pregnant women who attended prenatal care at the University hospitals of Nancy and Poitiers recruited before 24 weeks of amenorrhoea. | Twin pregnancies, women with known diabetes before pregnancy, insufficient French language skills and intention to move away from the recruitment area were excluded. | 2003–2006 | Nancy and | 1900 |
| INMA, Spain | Pregnant women who attended a prenatal care centre in the study region during weeks 6–10 of pregnancy. | Women who resided or intended to deliver outside the study area, who were aged under 16 years, who had twin or multiple pregnancies, who had assisted reproduction or who had communication problems were excluded. | 2003–2008 | Gipuzkoa | 2063 |
| KANC, Lithuania | Pregnant women who attended one of four prenatal care clinics affiliated to the hospitals of the Kaunas University of Medicine during first trimester of pregnancy. | Women who lived outside Kaunas municipality, had medical records of pregnancy induced hypertension and/or diabetes were excluded. | 2007–2008 | Kaunas | 4107 |
| MoBa, Norway | Recruitment at the first ultrasound (US) scan, ie, during the 17–18 weeks of gestation. All women who gave singleton births in the participating maternity units. | None | 1999–2008 | Oslo | 11 095 |
| RHEA, Greece | Pregnant women who attended US examination before 15 week of pregnancy with residence in and near Heraklion at Crete. | Women who were aged under 16 years or who had communication problems were excluded. | 2007–2008 | Heraklion | 1458 |
| Total | 31 472 |
BiB, Born in Bradford; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study.
Figure 1Flow chart describing design and available data. GIS, Geographic Intelligent Software; HELIX, Human Early Life Exposome; miRNA, microRNA; mtDNA, mitochondrial DNA. *Omics data available after quality control
Health outcomes harmonised across the entire cohort between birth and 5 years of age
| Health/development outcomes | Methods | BiB | EDEN | INMA | KANC | MoBa | RHEA | Total number of subjects in the harmonised dataset |
|
| ||||||||
| Birth weight | Measurements | √ | √ | √ | √ | √ | √ | 31 472 |
| Gestational duration | Medical records/ultrasound | √ | √ | √ | √ | √ | √ | 31 472 |
|
| ||||||||
| Repeated weight, height, BMI | Measurements and records | √ | √ | √ | √ | √ | √ | 28 305 |
| Waist circumference | Measurements | |||||||
| 1–2 years | √ | √ | √ | √ | 4598 | |||
| 4–5 years | √ | √ | √ | √ | 4275 | |||
| Skinfolds | Measurements | |||||||
| 1–2 years | √ | √ | √ | 3364 | ||||
| 4–5 years | √ | √ | √ | 2774 | ||||
| Blood pressure (4–5 years) | Measurements | √ | √ | √ | √ | 5182 | ||
| Cognition | Psychologist-administered tests and parental questionnaires | √ | √ | √ | 3470 | |||
| Motor skills, language | Psychologist-administered tests and parental questionnaires | √ | √ | √ | √ | √ | 10 245 | |
| Behaviour | Questionnaires | √ | √ | √ | √ | √ | √ | 12 644 |
| Asthma, wheeze | Questionnaires | √ | √ | √ | √ | √ | √ | 12 068 |
| Lung function (4–5 years) | Spirometry | √ | √ | √ | √ | 2719 |
BiB, Born in Bradford; BMI, body mass index; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study.
Exposure estimates available in the HELIX entire cohort and subcohort
| Exposure group | Description* | Pregnancy | Postnatal | Subcohort |
| Outdoor and urban exposure estimates available in the entire cohort and in the subcohort | ||||
| Atmospheric pollutants | NO2, PM2.5, PM10, PM2.5 (absorbance ratio) | √ * | √ | √ |
| Ultraviolet (UV) | Ambient UV radiation levels | √ | √ | √ |
| Surrounding natural space | Average normalised difference vegetation index within buffers of 100, 300 and 500 m | √ | √ | √ |
| Meteorology | Land surface temperature average in a buffer of 50 m | √ * | √ | √ |
| Built environment | Population density: inhabitants per km2
| √ | √ | √ |
| Traffic | Total traffic load of major roads in a 100 m buffer, total traffic load in a 100 m buffer, traffic density on nearest road and inverse distance to nearest road | √ | √ | √ |
| Road traffic noise | Day and night time road noise levels | √ | √ | √ |
| Contaminant exposure estimates available in the HELIX subcohort | ||||
| Organochlorine compounds | Blood concentrations of dichlorodiphenyldichloroethylene, dichlorodiphenyltrichloroethane, hexachlorobenzene and polychlorinated biphenyl—118, 68, 153, 170, 180. With and without lipid adjustment. | √ | – | √ |
| Brominated compounds | Blood concentrations of polybrominated diphenyl ether—47, 153. With and without lipid adjustment. | √ | – | √ |
| Perfluorinated alkylated substances | Blood concentrations of perfluorooctanoate, perfluorononanoate, perfluoroundecanoate, perfluorohexane sulfonate, perfluorooctane sulfonate | √ | – | √ |
| Metals and essential elements | Whole blood concentrations of arsenic, cadmium, cesium, cobalt, copper, lead, manganese, mercury, molybdenum, thallium, potassium, magnesium, sodium, selenium and zinc | √ | – | √ |
| Phthalate metabolites | Urine concentrations of monoethyl phthalate, mono-iso-butyl phthalate, mono-n-butyl phthalate, mono benzyl phthalate, mono-2-ethylhexyl phthalate, mono-2-ethyl-5-hydroxyhexyl phthalate, mono-2-ethyl-5-oxohexyl phthalate, mono-2-ethyl 5-carboxypentyl phthalate, mono-4-methyl-7-hydroxyoctyl phthalate, mono-4-methyl-7-oxooctyl phthalate. With and without creatinine adjustment. | √ | – | √ |
| Phenols | Urine concentrations of methyl paraben, ethyl paraben, bisphenol A, propyl paraben, N-butyl paraben, oxybenzone, triclosan. With and without creatinine adjustment. | √ | – | √ |
| Organophosphate pesticide metabolites | Urine concentrations of dimethyl phosphate, dimethyl thiophosphate, dimethyl dithiophosphate, diethyl phosphate, diethyl thiophosphate, diethyl dithiophosphate. With and without creatinine adjustment. | √ | – | √ |
| Tobacco smoking | Urine levels of cotinine. Questionnaire on active and passive smoking. | √ | – | √ |
| Water disinfection by-products | Total concentration of total trihalomethanes (THMs), chloroform and total brominated THMs estimated in tap water from water company concentration and distribution data. | √ | – | – |
| Indoor air | Prediction models for indoor air concentrations of NO2, PM2.5, PMabs, benzene and toluene, ethylbenzene, xylene using panel study data from indoor air samplers. | – | – | √ |
*Walkability indicator adapted from the previous walkability indexes45 46: calculated as the mean of the deciles of population density, street connectivity, facility richness index and land use Shannon’s Evenness Index within 300 m buffers, giving a walkability score ranging from 0 to 1.
ESCAPE, European Study of Cohorts for Air Pollution Effects; HELIX, Human Early Life Exposome; NO2, nitrogen dioxide; PM2.5, mass concentration of particles <2.5 µm in aerodynamical diameter; PM10, mass concentration of particles <10 µm in aerodynamical diameter; PMabs, absorbance of PM2.5 filters; a proxy for elemental carbon, which is the dominant light absorbing substance.
Omics features available in the HELIX subcohort and repeat child panel study
| Omics | Sample | Platform | Features | Subcohort (n=1300) | Second period child panel study |
| Proteomics | Plasma | Luminex kits: cytokines 30-plex, apoliprotein 5-plex and adipokine 15-plex | 36 | 1170 | 154 |
| Methylation | Buffy coat | 450K, Illumina | 386 518 | 1173 | 153 |
| Transcriptomics | Whole blood | HTA V.2.0, Affymetrix | 35 841 | 1010 | 127 |
| MicroRNA (miRNA) | Whole blood | SurePrint Human miRNA rel 21, Agilent | 330 | 941 | 123 |
| Urinary metabolomics | Urine | 1H NMR spectroscopy | 44 | 1198 | 153 |
| Serum metabolomics | Serum | AbsoluteIDQ p180 kit, Biocrates | 177 | 1198 | 154 |
| Telomere length | Buffy coat | Quantitative real-time PCR | 2 | 1166 | 153 |
*One child’s parents in the subcohort did not give genetic consent, therefore this child was excluded from all omics analyses.
HELIX, Human Early Life Exposome.
Measurements performed in the child and pregnancy panel studies
| Measurement | No. of subjects in child panel study* | No. of subjects in pregnancy panel study* | Description | Measurement point/period |
| Geolocation and mobility | 146 | 126 | Smartphone GPS with ExpoApp application installed | 7 days in each study period |
| Physical activity | 145 | 148 | Smartphone and Actigraph accelerometer | 7 days in each study period |
| NO2 | 154 | 158 | Passive samplers for NO2 installed in the home | 7 days in each study period |
| BTEX | 154 | 158 | Passive samplers for BTEX installed in the home | 7 days in each study period |
| PM2.5 | 92 | 90 | Active PM2.5 Cyclone pumps (BGI-400–4), carried by participants in backpack and installed in the home | Last 24 hours of each of the two study periods |
| Black carbon | 89 | 66 | MicroAthelometer (AE51) for continuous monitoring | Last 24 hours of each of the two study periods |
| UV | 69 | 141 | Electronic wrist band UV dosimeters | 7 days in each study period |
| Phthalates, phenols, organophosphate pesticides | 152 | – | Pool of bedtime and first morning urine | 4 separate days in one study period |
| Phthalates, phenols, organophosphate pesticides, cotinine | 152 | 154 | Pool of daily urine samples (2 or 3 per day) during 1 week | One pool in each of the two study periods |
| Phthalates | – | 44 | All morning and bed time urines during 1 week | 7 days in one study period |
| 1H NMR metabolomics | 22 | – | All morning and bed time urines during 1 week | 7 days in one study period |
| Lung function | 62 | – | Spirometry | Last day of period 1 and 2 |
| Blood pressure | 157 | 154 | OMRON 705-CPII automated oscillometric device | Last day of period 1 and 2 |
| Height and weight | 157 | 145 | Last day of period 1 and 2 |
*With data in both periods.
BTEX, benzene, toluene, ethylene and meta-xylene, para-xylene and ortho-xylene; 1H NMR, proton nuclear magnetic resonance; NO2, nitrogen dioxide; PM 2.5, mass concentration of particles <2.5 µm in aerodynamical diameter; UV, ultraviolet.
Comparison of basic characteristics between the HELIX entire cohort (n=31 472), the subcohort (n=1301) and the child panel study (n=157)
| Entire cohort | Subcohort | Panel study* | |
| (n=31 472) | (n=1301) | (n=157) | |
|
| |||
| Sex (%) | |||
| Male | 51.2 | 54.7† | 56.1 |
| Female | 48.8 | 45.4† | 43.9 |
| Birth weight, g (SD) | 3372 (547) | 3379 (508) | 3346 (479) |
| Gestational age, weeks (SD) | 39.7 (1.8) | 39.6 (1.7) | 39.5 (1.6) |
|
| |||
| Maternal age, years (SD) | 29.6 (5.2) | 30.8 (4.9)† | 31.0 (4.9)‡ |
| Maternal education (%) | |||
| Low | 22.7 | 6.8† | 6.8 |
| Middle | 25.7 | 34.5† | 34.5 |
| High | 51.6 | 51.8† | 51.8 |
| Maternal BMI* (%) | |||
| Underweight/normal weight | 58.6 | 60.9 | 58.1 |
| Overweight | 25.6 | 24.4 | 25.8 |
| Obesity | 15.8 | 14.7 | 16.1 |
| Country of origin of parents (%) | |||
| Both from other country | 21 | 11.1† | 5.2‡ |
| One parent from other country | 6.3 | 7.5† | 4.5‡ |
| Both parents from country of cohort | 65.7 | 81.4† | 90.3‡ |
| Parity (%) | |||
| 0 previous pregnancies | 50.7 | 45.9† | 42.4 |
| ≥1 previous pregnancies | 49.3 | 54.1† | 57.6 |
| Maternal smoking during pregnancy (%) | |||
| No | 87.9 | 83.1† | 85.3 |
| Yes | 12.1 | 14.8† | 14.7 |
*BMI grouped according to WHO categories for underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) and obese (≥30 kg/m2).
†P<0.05 comparing the subcohort (n=1301) with the entire cohort.
‡P<0.10 comparing the child panel study with non-panel subcohort children in the same cohorts (excluding MoBa).
HELIX, Human Early Life Exposome; MoBa, Norwegian Mother and Child Cohort Study.
HELIX subcohort characteristics
| Total | BiB | EDEN | INMA | KANC | MoBa | RHEA | |
| (n=1301) | (n=205) | (n=198) | (n=223) | (n=204) | (n=272) | (n=199) | |
| Age, years, median (IQR) | 8.1 (6.5; 8.9) | 6.6 (6.4; 6.8) | 11 (10; 11) | 8.8 (8.4; 9.2) | 6.4 (6.1; 6.8) | 8.4 (8.2; 8.8) | 6.5 (6.4; 6.6) |
| Sex, female (%) | 45.4 | 44.9 | 42.9 | 46.2 | 45.6 | 47.8 | 44.2 |
| Ethnicity, Caucasian (%) | 90 | 42.9* | 99.5 | 100 | 100 | 95.6 | 100 |
| Family affluence (%) | |||||||
| Low | 10.7 | 27.8 | 1 | 6.8 | 15.3 | 1.5 | 15.1 |
| Middle | 38.5 | 42.9 | 21.2 | 39.6 | 52.7 | 26.8 | 51.3 |
| High | 50.8 | 29.3 | 77.8 | 53.6 | 32 | 71.7 | 33.7 |
| Maternal smoking during pregnancy, | 14.8 | 12.2 | 23.7 | 24.7 | 6 | 3.4 | 21.2 |
| Environmental tobacco smoke, yes (%) | 34.3 | 27.3 | 24.8 | 31.5 | 40.1 | 18.8 | 69.4 |
| Fruit intake, times/week, median (IQR) | 9 (6; 18) | 16 (10; 21) | 6.6 (3.3; 14) | 7.5 (3.6; 12) | 7.3 (3.8; 9.6) | 8.5 (6.2; 14) | 14 (8.6; 21) |
| Vegetable intake, times/week, median (IQR) | 6.5 (4; 10) | 6 (4; 10) | 8.2 (4.4; 11) | 6 (3; 8.5) | 6 (3.5; 8.5) | 6.5 (4; 10) | 8.5 (6; 14) |
| Visits to fast food restaurant, take away times/week, median (IQR) | 0.13 (0.13; 0.5) | 0.5 (0.13; 1) | 0.13 (0.13; 0.5) | 0.13 (0.13; 0.5) | 0.13 (0; 0.13) | 0.5 (0.13; 0.5) | 0.13 (0.13; 0.5) |
| Moderate to vigorous physical activity, | 36 (22; 55) | 42 (32; 62) | 17 (7.8; 29) | 26 (17; 44) | 42 (35; 57) | 35 (23; 63) | 49 (36; 61) |
| Food allergy, yes (%) | 20.7 | 21 | 16.7 | 35 | 16.2 | 18.8 | 15.6 |
| Asthma, yes (%) | 11.6 | 18.5 | 20.2 | 3.6 | 7.8 | 11.4 | 9.1 |
| Child zBMI (%) | |||||||
| Underweight/normal weight | 71.4 | 77.1 | 73.7 | 57.7 | 70 | 84.1 | 62.8 |
| Overweight | 18.8 | 15.1 | 21.2 | 23.6 | 20.2 | 6.2 | 20.6 |
| Obesity | 9.9 | 7.8 | 5.1 | 18.6 | 9.9 | 2.6 | 16.6 |
| Conners ADHD symptoms, yes (%) | 10.1 | 9.3 | 8.6 | 6.6 | 15.2 | 4.4 | 10.8 |
| CBCL, total problems, median (IQR) | 21 (10; 33) | 15 (8; 28) | 26 (16; 37) | 22 (12; 40) | 27 (17; 42) | 9 (5; 17) | 26 (16; 36) |
*44.9% of the subcohort BiB population is from South Asian ethnic origin and 12.1% of other ethnicity.
ADHD, Attention Deficit Hyperactivity Disorder; BiB, Born in Bradford; CBCL, child behaviour checklist; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; HELIX, Human Early Life Exposome; INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study; zBMI, age standardized z-score for body mass index.
Figure 2Prevalence of children with food allergy, asthma, overweight/obesity and ADHD symptoms in the HELIX subcohort at 6–11 years. BiB, Born in Bradford; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; HELIX, Human Early Life Exposome; INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study; zBMI, age standardized z-score for body mass index.